Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms.
OBJECTIVE
To determine whether statin use is associated with a decreased risk of developing benign prostatic enlargement (BPE) and lower urinary tract symptoms (LUTS).


METHODS
We conducted a retrospective, population-based cohort study of 2447 men, 40-79 years of age, residing in Olmsted County, MN, USA, in 1990, and followed these men biennially through 2007. Cox proportional hazard models were used to assess associations between statin use and new onset of moderate/severe LUTS (American Urological Association Symptom Index score >7), a decreased maximum urinary flow rate (<12 mL/s) or BPE (prostate volume >30 mL).


RESULTS
Statin use was inversely associated with new onset of LUTS (Hazard ratio (HR) 0.39; 95% confidence interval (CI) 0.31-0.49), a decreased maximum flow rate (HR 0.53; 95% CI 0.34-0.82) and BPE (HR 0.40; 95% CI 0.23-0.69) after adjustment for baseline age and body mass index, diabetes, hypertension, coronary heart disease, smoking, alcohol use, activity level and non-steroidal anti-inflammatory use. The longest duration of statin use was associated with the lowest risk of developing each outcome (all tests for trend: P < 0.001).


CONCLUSIONS
In this study, statin use was associated with a 6.5- to 7-year delay in the new onset of moderate/severe LUTS or BPE. While men typically take statin medications to prevent coronary heart disease events and related outcomes, these data suggest that men who use statins may also receive urologic benefits.
St Sauver
Jennifer L
JL
Division of Epidemiology, Departments of Urology and Health Sciences Research and Cardiology, Mayo Clinic College of Medicine, Rochester, MN, USA. stsauver.jennifer@mayo.edu
Jacobsen
Steven J
SJ
Jacobson
Debra J
DJ
McGree
Michaela E
ME
Girman
Cynthia J
CJ
Nehra
Ajay
A
Roger
Veronique L
VL
Lieber
Michael M
MM
D000328:Adult; D000368:Aged; D004812:Epidemiologic Methods; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D008910:Minnesota / Q000453:epidemiology; D009929:Organ Size; D011467:Prostate / Q000473:pathology; D011470:Prostatic Hyperplasia / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control*; D011472:Prostatitis / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
JAMA. 1993 Aug 18;270(7):860-4
7688054
J Urol. 2001 May;165(5):1521-5
11342910
Curr Pharm Des. 2009;15(5):467-78
19199975
Int J Epidemiol. 1994 Dec;23(6):1198-205
7536718
Mayo Clin Proc. 1996 Mar;71(3):266-74
8594285
Curr Urol Rep. 2008 Jul;9(4):272-8
18765125
Int J Obes (Lond). 2005 Mar;29(3):310-6
15672112
Am J Epidemiol. 2006 Jul 1;164(1):41-6
16611664
Eur Urol. 2007 Aug;52(2):503-9
17343981
Expert Opin Drug Saf. 2008 Nov;7(6):717-25
18983218
J Urol. 2005 Jun;173(6):1923-5
15879782
Am J Med. 2004 Aug 15;117(4):228-33
15308431
Ann Intern Med. 2002 Mar 5;136(5):341-8
11874305
Int Braz J Urol. 2008 Sep-Oct;34(5):555-61; discussion 561-2
18986558
J Clin Epidemiol. 2001 Sep;54(9):935-44
11520654
Urology. 1998 Mar;51(3):428-36
9510348
J Natl Cancer Inst. 2008 Nov 5;100(21):1511-8
18957682
J Clin Epidemiol. 2002 Jun;55(6):593-601
12063101
Lancet. 1991 Aug 24;338(8765):469-71
1714529
J Urol. 2010 Aug;184(2):494-9
20620405
Diabetes Care. 2008 Mar;31(3):476-82
18071006
Urology. 2006 Dec;68(6):1198-205
17169643
Eur Urol. 2007 Oct;52(4):964-72
17618043
J Urol. 1999 Apr;161(4):1174-9
10081864
Eur Urol. 1999 Apr;35(4):277-84
10087388
Urology. 1993 Dec;42(6):663-71
7504848
Am J Epidemiol. 2006 Oct 15;164(8):760-8
16905643
Mayo Clin Proc. 2000 Jul;75(7):681-7
10907382
BJU Int. 2007 Feb;99(2):347-54
17313423
J Urol. 1992 Nov;148(5):1549-57; discussion 1564
1279218
Urology. 2009 Mar;73(3):544-8
19118873
Trends Endocrinol Metab. 2008 May-Jun;19(4):113-21
18356074
Am J Epidemiol. 2003 May 15;157(10):906-14
12746243
BJU Int. 2008 Feb;101(3):313-8
18005202
J Urol. 2007 Apr;177(4):1395-400; quiz 1591
17382740
J Urol. 2005 Apr;173(4):1309-13
15758787